

Thomas Michael Marti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8619758/publications.pdf>

Version: 2024-02-01

49
papers

1,683
citations

331538

21
h-index

289141

40
g-index

53
all docs

53
docs citations

53
times ranked

2888
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma. <i>Theranostics</i> , 2022, 12, 167-185.	4.6	6
2	Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 25.	3.5	6
3	Functional and molecular characterization of PD1 ⁺ tumor-infiltrating lymphocytes from lung cancer patients. <i>Oncolmunology</i> , 2022, 11, 2019466.	2.1	4
4	Multi-scale integrative analyses identify THBS2 ⁺ cancer-associated fibroblasts as a key orchestrator promoting aggressiveness in early-stage lung adenocarcinoma. <i>Theranostics</i> , 2022, 12, 3104-3130.	4.6	23
5	Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational study. <i>Respiratory Research</i> , 2022, 23, .	1.4	3
6	CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for <i>FGFR1</i> -Amplified Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3121-3133.	0.4	12
7	Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5 α -deoxy-5-fluorocytidine (5 α -DFCR). <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 138.	3.5	9
8	Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis. <i>Cell Death and Disease</i> , 2021, 12, 406.	2.7	10
9	Pulmonary mesenchymal stem cells are engaged in distinct steps of host response to respiratory syncytial virus infection. <i>PLoS Pathogens</i> , 2021, 17, e1009789.	2.1	6
10	Synergistic effects of <i>FGFR1</i> and <i>PLK1</i> inhibitors target a metabolic liability in <i>KRAS</i> mutant cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e13193.	3.3	11
11	Peritumoral CD90 ⁺ CD73 ⁺ cells possess immunosuppressive features in human non-small cell lung cancer. <i>EBioMedicine</i> , 2021, 73, 103664.	2.7	5
12	Beyond DNA Repair: DNA-PKcs in Tumor Metastasis, Metabolism and Immunity. <i>Cancers</i> , 2020, 12, 3389.	1.7	19
13	EpCAM ⁺ CD73 ⁺ mark epithelial progenitor cells in postnatal human lung and are associated with pathogenesis of pulmonary disease including lung adenocarcinoma. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L794-L809.	1.3	7
14	Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer. <i>Cancers</i> , 2020, 12, 3273.	1.7	24
15	CD90 ⁺ CD146 ⁺ identifies a pulmonary mesenchymal cell subtype with both immune modulatory and perivascular-like function in postnatal human lung. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 318, L813-L830.	1.3	15
16	CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 661-672.	1.9	26
17	HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant <i>KRAS</i> -mutant lung cancer. <i>Oncogenesis</i> , 2019, 8, 45.	2.1	38
18	Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2019, 11, 1502.	1.7	27

#	ARTICLE	IF	CITATIONS
19	Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment. <i>Cancer Cell International</i> , 2019, 19, 317.	1.8	19
20	mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. <i>Oncogene</i> , 2019, 38, 622-636.	2.6	37
21	Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549. <i>Neoplasia</i> , 2019, 21, 185-196.	2.3	38
22	Characterization of lung resident-mesenchymal stromal/stem cells from paediatric donors. , 2019, , .		0
23	Human microvasculature-on-a chip: anti-neovasculogenetic effect of nintedanib in vitro. <i>Angiogenesis</i> , 2018, 21, 861-871.	3.7	36
24	Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2018, 119, 65-75.	2.9	26
25	Glycine decarboxylase and HIF-1 α expression are negative prognostic factors in primary resected early-stage non-small cell lung cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 323-330.	1.4	22
26	Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 312, L42-L55.	1.3	13
27	Increased PD-L1 expression and IL-6 secretion characterize human lung tumor-derived perivascular-like cells that promote vascular leakage in a perfusable microvasculature model. <i>Scientific Reports</i> , 2017, 7, 10636.	1.6	35
28	23P Prolonged pemetrexed pretreatment increases efficiency of ionizing radiation combination therapy and correlates with the persistence of treatment-induced DNA damage in lung cancer cells. <i>Journal of Thoracic Oncology</i> , 2016, 11, S65.	0.5	0
29	22P Increased schedule-dependent efficiency of pemetrexed-cisplatin combination therapy eliminates resistant lung cancer stem-like cells associated with EMT. <i>Journal of Thoracic Oncology</i> , 2016, 11, S64-S65.	0.5	0
30	98O: Characterization of tumor infiltrating lymphocytes in resectable early stage non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, S99.	0.5	0
31	Schedule-dependent increased efficiency of pemetrexed-ionizing radiation combination therapy elicits a differential DNA damage response in lung cancer cells. <i>Cancer Cell International</i> , 2016, 16, 66.	1.8	4
32	18P Epithelial-to-mesenchymal transition (EMT) is required for resistance to anti-folate chemotherapy in lung cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, S63.	0.5	3
33	Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT. <i>BMC Cancer</i> , 2016, 16, 125.	1.1	34
34	Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer. <i>Cell Death and Disease</i> , 2015, 6, e1824-e1824.	2.7	70
35	Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress. <i>Molecular Oncology</i> , 2014, 8, 1747-1759.	2.1	13
36	A microfluidic platform for chemoresistive testing of multicellular pleural cancer spheroids. <i>Lab on A Chip</i> , 2014, 14, 1198-1205.	3.1	93

#	ARTICLE	IF	CITATIONS
37	Components of homologous recombination and translesion synthesis (TLS) in pemetrexed/cisplatin-treated non-small-cell lung cancer (NSCLC) patients (p).. Journal of Clinical Oncology, 2013, 31, 11028-11028.	0.8	0
38	Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin. BMC Cancer, 2012, 12, 571.	1.1	104
39	Differential Effects of Lovastatin on Cisplatin Responses in Normal Human Mesothelial Cells versus Cancer Cells: Implication for Therapy. PLoS ONE, 2012, 7, e45354.	1.1	21
40	Inhibition of REV3 Expression Induces Persistent DNA Damage and Growth Arrest in Cancer Cells. Neoplasia, 2011, 13, 961-IN28.	2.3	58
41	Translesion DNA synthesis in the context of cancer research. Cancer Cell International, 2011, 11, 39.	1.8	45
42	Cockayne syndrome exhibits dysregulation of p21 and other gene products that may be independent of transcription-coupled repair. Neuroscience, 2007, 145, 1300-1308.	1.1	17
43	Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Molecular Cancer, 2007, 6, 66.	7.9	57
44	Pol δ is required for DNA replication during nucleotide deprivation by hydroxyurea. Oncogene, 2007, 26, 5713-5721.	2.6	39
45	H2AX phosphorylation within the G1 phase after UV irradiation depends on nucleotide excision repair and not DNA double-strand breaks. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9891-9896.	3.3	321
46	DNA repair nucleases. Cellular and Molecular Life Sciences, 2004, 61, 336-354.	2.4	77
47	Different frameshift mutation spectra in non-repetitive DNA of MutS Δ - and MutL Δ -deficient fission yeast cells. DNA Repair, 2003, 2, 571-580.	1.3	8
48	Repair of Damaged and Mismatched DNA by the XPC Homologues Rhp41 and Rhp42 of Fission Yeast. Genetics, 2003, 164, 457-467.	1.2	15
49	DNA mismatch repair and mutation avoidance pathways. Journal of Cellular Physiology, 2002, 191, 28-41.	2.0	222